Literature DB >> 10923853

Laboratory-acquired human glanders--Maryland, May 2000.

.   

Abstract

On May 5, 2000, the Baltimore City Health Department was notified by hospital infection-control staff of a serious systemic febrile illness in a microbiologist whose research at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) involved several pathogenic bacteria, including Burkholderia mallei, the causative agent of glanders. This report summarizes the first human case of glanders in the United States since 1945, and emphasizes the importance of considering occupational exposures among laboratory workers with a febrile illness, the difficulty of characterizing unusual agents, including potential agents of biological terrorism such as glanders using routine laboratory techniques, the appropriate isolation practices for patients who may be infected by these agents, and laboratory safety.

Entities:  

Mesh:

Year:  2000        PMID: 10923853

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  17 in total

1.  In vitro antibiotic susceptibilities of Burkholderia mallei (causative agent of glanders) determined by broth microdilution and E-test.

Authors:  H S Heine; M J England; D M Waag; W R Byrne
Journal:  Antimicrob Agents Chemother       Date:  2001-07       Impact factor: 5.191

2.  Preliminary evaluation of the API 20NE and RapID NF plus systems for rapid identification of Burkholderia pseudomallei and B. mallei.

Authors:  Mindy B Glass; Tanja Popovic
Journal:  J Clin Microbiol       Date:  2005-01       Impact factor: 5.948

Review 3.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

4.  Efficacy of postexposure therapy against glanders in mice.

Authors:  David M Waag
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  Humoral immune responses in a human case of glanders.

Authors:  David M Waag; Marilyn J England; David DeShazer
Journal:  Clin Vaccine Immunol       Date:  2012-03-07

6.  Molecular and physical characterization of Burkholderia mallei O antigens.

Authors:  Mary N Burtnick; Paul J Brett; Donald E Woods
Journal:  J Bacteriol       Date:  2002-02       Impact factor: 3.490

7.  In Vitro and In Vivo studies of monoclonal antibodies with prominent bactericidal activity against Burkholderia pseudomallei and Burkholderia mallei.

Authors:  Shimin Zhang; Shaw-Huey Feng; Bingjie Li; Hyung-Yong Kim; Joe Rodriguez; Shien Tsai; Shyh-Ching Lo
Journal:  Clin Vaccine Immunol       Date:  2011-03-30

8.  Nonviable Burkholderia mallei induces a mixed Th1- and Th2-like cytokine response in BALB/c mice.

Authors:  Kei Amemiya; Gary V Bush; David DeShazer; David M Waag
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 9.  Treatment of neuroterrorism.

Authors:  Katharina M Busl; Thomas P Bleck
Journal:  Neurotherapeutics       Date:  2012-01       Impact factor: 7.620

10.  Comparison of the in vitro and in vivo susceptibilities of Burkholderia mallei to Ceftazidime and Levofloxacin.

Authors:  Barbara M Judy; Gregory C Whitlock; Alfredo G Torres; D Mark Estes
Journal:  BMC Microbiol       Date:  2009-05-09       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.